Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan.
This investigation estimates and compares, for the first time, the distribution of body mass index (BMI: kg/m(2)) and the prevalence of obesity among Chinese outpatients with schizophrenia treated with antipsychotics. The BMI of 201 outpatients with schizophrenia-spectrum disorders was studied via a cross-sectional naturalistic study. This investigation also compared the BMI of the subjects with a Taiwanese reference population. This investigation found no significant difference in the prevalence of obesity between male and female subjects. The prevalence of obesity among male and female patients in this investigation was, respectively, 2.74- and 2.51-fold greater than the Taiwanese reference population, and the prevalence of severe obesity among male and female patients was 4.66- and 3.53-fold greater than that in the Taiwanese reference population, respectively. The rate of severe obesity was especially high in patients treated with olanzapine. Atypical antipsychotics other than olanzapine did not seem to be more closely associated with obesity or severe obesity compared to typical antipsychotics.
Hsiao
Cheng-Cheng
CC
Department of Psychiatry, Chang Gung Memorial Hospital, Keelung, Taiwan.
Ree
Shao-Chun
SC
Chiang
Yuan-Lin
YL
Yeh
Song-So
SS
Chen
Chih-Ken
CK
D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology; D009767:Obesity, Morbid / Q000139:chemically induced / Q000453:epidemiology; D000077152:Olanzapine; D012016:Reference Values; D012559:Schizophrenia / Q000188:drug therapy*; D012737:Sex Factors; D013624:Taiwan
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine